{
    "root": "2145b392-7aac-44c6-83fd-3a9d88837167",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Phytonadione",
    "value": "20250303",
    "ingredients": [
        {
            "name": "PHYTONADIONE",
            "code": "A034SE7857"
        },
        {
            "name": "ACACIELLA ANGUSTISSIMA BARK",
            "code": "ID3K20OAXF"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        }
    ],
    "indications": {
        "text": "phytonadione tablets indicated treatment adults following coagulation disorders due faulty formation factors ii , vii , ix x caused vitamin k deficiency interference vitamin k activity . \u2022anticoagulant-induced hypoprothrombinemia caused coumarin indanedione derivatives . \u2022hypoprothrombinemia secondary antibacterial therapy . \u2022hypoprothrombinemia secondary factors limiting absorpsion synthesis vitamin k , e.g . , obstructive jaundice , biliary fistula , sprue , ulcerative colitis , celiac disease , intestinal resection , cystic fibrosis pancrease , regional enteritis . \u2022other drug-induced hypoprothrombinemia definitely shown result due interference vitamin k metabolism , e.g . , salicylates .",
        "doid_entities": [
            {
                "text": "vitamin k deficiency (DOID:11249)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11249"
            },
            {
                "text": "k deficiency (DOID:13582)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13582"
            },
            {
                "text": "hypoprothrombinemia (DOID:2235)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2235"
            },
            {
                "text": "obstructive jaundice (DOID:13603)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13603"
            },
            {
                "text": "ulcerative colitis (DOID:8577)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8577"
            },
            {
                "text": "colitis (DOID:0060180)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060180"
            },
            {
                "text": "celiac disease (DOID:10608)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10608"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "cystic fibrosis (DOID:1485)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1485"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "cystic fibrosis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_586"
            }
        ]
    },
    "contraindications": {
        "text": "\u2022 anticoagulant-induced prothrombin deficiency : 2.5 mg 10 mg 25 mg. ( 2.2 ) \u2022 hypoprothrombinemia due causes : 2.5 mg 25 mg . ( 2.2 ) \u2022 must given bile salts endogenous supply bile gastrointestinal track deficient . ( 2.1 )",
        "doid_entities": [
            {
                "text": "prothrombin deficiency (DOID:2235)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2235"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "phytonadione tablets usp , 5 mg supplied light yellow yellow colored , round , scored tablets , debossed \u201c aa \u201d \u201c 05 \u201d either side scoring plain side . available : cartons 20 tablets ( 10 tablets blister pack x 2 ) , ndc 0904-6882-10 storage store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . always protect phytonadione tablets , usp light . store tightly closed original container carton contents used .",
    "adverseReactions": "phytonadione tablets contraindicated patients history hypersensitivity reaction phytonadione inactive ingredients [ description ( 11 ) ] .",
    "indications_original": "Phytonadione tablets are indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity.\n                  \n                     \n                        \u2022Anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives. \n                     \n                        \u2022Hypoprothrombinemia secondary to antibacterial therapy. \n                     \n                        \u2022Hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis.\n                     \n                        \u2022Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.",
    "contraindications_original": "\u2022 Anticoagulant-Induced Prothrombin Deficiency: 2.5 mg to 10 mg or up to 25 mg. (2.2) \u2022 Hypoprothrombinemia Due to Other Causes: 2.5 mg to 25 mg or more. (2.2) \u2022 Must be given with bile salts when endogenous supply of bile to gastrointestinal track is deficient. (2.1)",
    "warningsAndPrecautions_original": "Phytonadione Tablets USP, 5 mg are supplied as light yellow to yellow colored, round, scored tablets, debossed with \u201cAA\u201d and \u201c05\u201d on either side of scoring and plain on the other side.\n                  They are available:\n                  Cartons of 20 tablets (10 tablets each blister pack x 2), NDC 0904-6882-10\n                  \n                     \n                        Storage \n                     \n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted between 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature]. \n                  Always protect phytonadione tablets, USP from light. \n                   Store in tightly closed original container and carton until contents have been used.",
    "adverseReactions_original": "Phytonadione tablets are contraindicated in patients with a history of a hypersensitivity reaction to phytonadione or inactive ingredients [see Description (\n                        11)].",
    "drug": [
        {
            "name": "Phytonadione"
        }
    ]
}